Last updated: 2026-10-13 09:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
BIOMERICA INC. (BMRA) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $1.82, with a market capitalisation of $8.44M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.45 to $3.21. This page covers its latest market performance, valuation, price trends and company information.
$8.44M | |
$1.90 | |
$187.12 | |
$1.45 | |
$1.84 | |
4.93K | |
72.11K | |
-- | |
$3.21 | |
$1.45 | |
-- | |
-- |
BIOMERICA INC. (BMRA) is trading at $1.83 in pre-market trading as of 2026-10-12 23:40:00, down 0.28% ($0.01) from the previous close of $1.84
Pre-market trading shows how investors are pricing BMRA before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, BIOMERICA INC. (BMRA) moved from $2.14 to $1.82, representing a decline of 15.27% ($0.33).
The stock traded between $1.82 and $2.23 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 15.74 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 20.7%
BMRA is currently trading at $1.82, placing it 20.7% of the way from its 52-week low of $1.45 to its 52-week high of $3.21. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 50 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BIOMERICA INC. (BMRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.